MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.

Merck KGaA's experimental multiple sclerosis (MS) drug missed the primary goal in highly anticipated late-stage trials, dealing a major blow to the German company's growth ambitions and hitting ...

Merck, a leading science and technology company, today announced that data for approved and investigational multiple sclerosis (MS) treatments, MAVENCLAD ® (Cladribine Tablets) and Rebif ...

Merck KGaA’s shares fell around 13% after its multiple sclerosis drug evobrutinib didn’t meet a key goal in late-stage trials.

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end of the programme ...

Merck in Neurology and Immunology Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS).

German drugmaker Merck Serono is one step closer to releasing the first pill to treat multiple sclerosis, the company said Friday. In a press statement, Merck said that patients taking cladribine ...

In addition to Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases ...

The CEO of Germany's Merck KGaA said the company's experimental multiple sclerosis drug can be a "blockbuster", an industry term for annual sales that exceed $1 billion, even after concerns ...

Merck Serono and Bionomics Announce Multiple Sclerosis Development and Licensing Agreement - Bionomics and Merck Serono to Collaborate to Discover and Develop Novel, Oral Treatment for MS ...

Merck KGaA’s highly anticipated experimental multiple sclerosis (MS) drug failed to meet its primary endpoint in two Phase 3 trials, the company announced this week. The EVOLUTION trials found that ...

Merck KGaA (MRK.XE) said on Wednesday that a study of evobrutinib in relapsing multiple sclerosis has yielded positive results. The phase 2b study demonstrated that patients who received ...